暂无 | 1799711-22-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 中文名称: 暂无
• 英文名称: dFKBP-1
• 英文别名: [(1R)-3-(3,4-dimethoxyphenyl)-1-[3-[[4-[4-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]butylamino]-4-oxobutanoyl]amino]phenyl]propyl] (2S)-1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
• CAS: 1799711-22-0
• 化学式: C₅₃H₆₄N₆O₁₄
• 分子量: 1009.1
• InChiKey: RIBCWKRMNKOGRN-GGJINPDOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  73
• 可旋转键数：
  25
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  262
• 氢给体数：
  4
• 氢受体数：
  14

文献信息

• METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20160176916A1

  公开（公告）日：2016-06-23

  The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.

  本申请提供了作为蛋白质降解诱导基团的双功能化合物。本申请还涉及通过使用将结合脑白质蛋白的基团与能够结合到靶向蛋白的配体相连的双功能化合物来实现内源蛋白的靶向降解的方法，该方法可用于治疗增殖性疾病。本申请还提供了制备本申请化合物及其中间体的方法。
• Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
  申请人：DeuteRx, LLC

  公开号：US10189858B2

  公开（公告）日：2019-01-29

  The invention provides deuterium-enriched isoindolinonyl-piperidinonyl conjugates, deuterium-enriched oxoquinazolin-3(4H)-yl-piperidinonyl conjugates, pharmaceutical compositions, and methods of using such conjugates and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.

  本发明提供了富氘的异吲哚啉基-哌啶壬基共轭物、富氘的噁喹唑啉-3(4H)-基-哌啶壬基共轭物、药物组合物，以及使用这些共轭物和药物组合物治疗癌症、血管生成障碍、免疫障碍和其他疾病的方法。
• Methods to induce targeted protein degradation through bifunctional molecules
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10464925B2

  公开（公告）日：2019-11-05

  The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.

  本申请提供了作为蛋白质降解诱导分子的双功能化合物。本申请还涉及通过使用双官能化合物靶向降解内源性蛋白质的方法，该双官能化合物将脑龙结合分子与能够与靶向蛋白质结合的配体连接起来，可用于治疗增殖性疾病。本申请还提供了制造本申请化合物及其中间体的方法。
• Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US11046954B2

  公开（公告）日：2021-06-29

  This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

  本发明属于利用靶向蛋白降解调节嵌合抗原受体免疫效应细胞（例如 T 细胞（CAR-T））疗法以调节相关不良炎症反应（例如细胞因子释放综合征和肿瘤溶解综合征）的组合物和方法领域。
• DEUTERIUM-ENRICHED ISOINDOLINONYL-PIPERIDINONYL CONJUGATES AND OXOQUINAZOLIN-3(4H)-YL-PIPERIDINONYL CONJUGATES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
  申请人：DeuteRx, LLC

  公开号：US20180118758A1

  公开（公告）日：2018-05-03

  The invention provides deuterium-enriched isoindolinonyl-piperidinonyl conjugates, deuterium-enriched oxoquinazolin-3(4H)-yl-piperidinonyl conjugates, pharmaceutical compositions, and methods of using such conjugates and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.